Short-term outcomes in patients with center-involving diabetic macular edema after a single dose of intravitreal bevacizumab

BACKGROUND: A significant portion of diabetic macular edema (DME) is refractory to anti-vascular endothelial growth factor (anti-VEGF) agents. This study investigates morphological and functional outcomes to a single intravitreal bevacizumab (IVB) injection in patients with center-involving DME (ciD...

Descripción completa

Detalles Bibliográficos
Autores principales: Turski, Christopher A., Jacobs, Mitchell A., Abou-Jaoude, Michelle M., Fowler, Nicholas H., Harpole, Ryan, Altman, Emily, Chadwell, John B., Kindl, Gabriel, James, Hayley R., Reddy, Shivani V., Maldonado, Ramiro S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673338/
https://www.ncbi.nlm.nih.gov/pubmed/36397121
http://dx.doi.org/10.1186/s40942-022-00430-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673338/
https://www.ncbi.nlm.nih.gov/pubmed/36397121
http://dx.doi.org/10.1186/s40942-022-00430-z

Ejemplares similares